These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Möllgård L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennström L; Höglund M; Juliusson G Leukemia; 2011 Jul; 25(7):1128-34. PubMed ID: 21502956 [TBL] [Abstract][Full Text] [Related]
6. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Chen Y; Kantarjian H; Wang H; Cortes J; Ravandi F Cancer; 2012 Dec; 118(23):5811-8. PubMed ID: 22707337 [TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Frankel SR; Eardley A; Heller G; Berman E; Miller WH; Dmitrovsky E; Warrell RP Ann Intern Med; 1994 Feb; 120(4):278-86. PubMed ID: 8291820 [TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214 [TBL] [Abstract][Full Text] [Related]
9. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300 [TBL] [Abstract][Full Text] [Related]
10. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. Bally C; Fadlallah J; Leverger G; Bertrand Y; Robert A; Baruchel A; Guerci A; Recher C; Raffoux E; Thomas X; Leblanc T; Idres N; Cassinat B; Vey N; Chomienne C; Dombret H; Sanz M; Fenaux P; Adès L J Clin Oncol; 2012 May; 30(14):1641-6. PubMed ID: 22473162 [TBL] [Abstract][Full Text] [Related]
11. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Vahdat L; Maslak P; Miller WH; Eardley A; Heller G; Scheinberg DA; Warrell RP Blood; 1994 Dec; 84(11):3843-9. PubMed ID: 7949141 [TBL] [Abstract][Full Text] [Related]
12. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Kanamaru A; Takemoto Y; Tanimoto M; Murakami H; Asou N; Kobayashi T; Kuriyama K; Ohmoto E; Sakamaki H; Tsubaki K Blood; 1995 Mar; 85(5):1202-6. PubMed ID: 7858250 [TBL] [Abstract][Full Text] [Related]
13. The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia. Jillella AP; Kota VK Blood Rev; 2018 Mar; 32(2):89-95. PubMed ID: 29033137 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985 [TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. Lachaine J; Mathurin K; Barakat S; Couban S Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894 [TBL] [Abstract][Full Text] [Related]
17. Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone. Advani SH; Nair R; Bapna A; Gladstone B; Kadam P; Saikia TK; Parekh PM; Gopal R; Nair CN Am J Hematol; 1999 Feb; 60(2):87-93. PubMed ID: 9929098 [TBL] [Abstract][Full Text] [Related]
18. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia. Eardley AM; Heller G; Warrell RP Leukemia; 1994 Jun; 8(6):934-9. PubMed ID: 8207987 [TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341 [TBL] [Abstract][Full Text] [Related]
20. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Warrell RP; Maslak P; Eardley A; Heller G; Miller WH; Frankel SR Leukemia; 1994; 8 Suppl 2():S33-7. PubMed ID: 7815834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]